335 related articles for article (PubMed ID: 25878241)
1. Evolution of MRI appearances due to progressive multifocal leucoencephalopathy following natalizumab treatment for multiple sclerosis.
Campbell S; Kanodia AK; O'Riordan J
BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25878241
[No Abstract] [Full Text] [Related]
2. [Natalizumab can induce progressive multifocal leucoencephalopathy].
Theódórsdóttir A; Blaabjerg M; Falah M
Ugeskr Laeger; 2014 Aug; 176(35):. PubMed ID: 25293706
[TBL] [Abstract][Full Text] [Related]
3. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.
Zhang Y; Wright C; Flores A
J Med Case Rep; 2018 Jul; 12(1):187. PubMed ID: 29960601
[TBL] [Abstract][Full Text] [Related]
4. The 'across the pons' sign: A possible novel radiographic finding in natalizumab-associated progressive multifocal leukoencephalopathy.
Budhram A; Pelikan JB; Kremenchutzky M; Sharma M
J Neurol Sci; 2017 Apr; 375():304-306. PubMed ID: 28320156
[No Abstract] [Full Text] [Related]
5. Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C; Wijburg MT; Hartung HP; Killestein J; Adams O; Wattjes MP
J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1092-1094. PubMed ID: 28490505
[No Abstract] [Full Text] [Related]
6. A giant MS plaque mimicking PML during natalizumab treatment.
Twyman C; Berger JR
J Neurol Sci; 2010 Apr; 291(1-2):110-3. PubMed ID: 20144466
[TBL] [Abstract][Full Text] [Related]
7. Quantitative electroencephalography supports diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Classen G; Classen C; Bernasconi C; Brandt C; Gold R; Chan A; Hoepner R
J Neurovirol; 2019 Feb; 25(1):133-136. PubMed ID: 30414049
[TBL] [Abstract][Full Text] [Related]
8. Fatal natalizumab-associated progressive multifocal leukoencephalopathy with initial low JCV antibody index in a multiple sclerosis patient.
Hay M; Leguy S; Cahagne V; Lassalle N; Le Page E; Michel L
Rev Neurol (Paris); 2024 Jun; 180(6):565-567. PubMed ID: 38429158
[No Abstract] [Full Text] [Related]
9. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
Martí G; Río J; Rovira À; Auger C; Tintoré M; Sastre-Garriga J; Vidal A; Castilló J; Montalban X
Rev Neurol; 2015 Feb; 60(4):164-8. PubMed ID: 25670046
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
Pitarokoili K; Gold R
Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
[No Abstract] [Full Text] [Related]
11. CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.
Pignolet B; Schwab N; Schneider-Hohendorf T; Bucciarelli F; Biotti D; Averseng-Peaureaux D; Outteryck O; Ongagna JC; de Sèze J; Brochet B; Ouallet JC; Debouverie M; Pittion S; Defer G; Derache N; Hautecoeur P; Tourbah A; Labauge P; Castelnovo G; Clavelou P; Berger E; Pelletier J; Rico A; Zéphir H; Laplaud D; Wiertlewski S; Camu W; Thouvenot E; Casez O; Moreau T; Fromont A; Vukusic S; Papeix C; Vermersch P; Comabella M; Lebrun-Frenay C; Wiendl H; Brassat D;
Neurology; 2016 Dec; 87(23):2491-2494. PubMed ID: 27815407
[No Abstract] [Full Text] [Related]
12. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO.
Enzinger C
Mult Scler; 2017 May; 23(6):767-770. PubMed ID: 28287038
[No Abstract] [Full Text] [Related]
13. Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
Maloney E; Molloy A; Al Hussona M; O'Donnell L; Killeen R; McGuigan C
J Neurol; 2017 Feb; 264(2):401-403. PubMed ID: 28039520
[No Abstract] [Full Text] [Related]
14. Refractory epilepsy following natalizumab associated PML.
Abkur TM; Kearney H; Hennessy MJ
Mult Scler Relat Disord; 2018 Feb; 20():1-2. PubMed ID: 29253743
[TBL] [Abstract][Full Text] [Related]
15. Cyclical suicidal ideation following natalizumab infusion for multiple sclerosis.
Nagesh O; Bastiampillai T; Fisher L; Mohan T
Aust N Z J Psychiatry; 2015 Jul; 49(7):668-9. PubMed ID: 25688123
[No Abstract] [Full Text] [Related]
16. Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution.
Scarpazza C; Signori A; Prosperini L; Sormani MP; Cosottini M; Capra R; Gerevini S;
J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):261-267. PubMed ID: 30389778
[TBL] [Abstract][Full Text] [Related]
17. Natalizumab in Multiple Sclerosis: Long-Term Management.
Clerico M; Artusi CA; Liberto AD; Rolla S; Bardina V; Barbero P; Mercanti SF; Durelli L
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468254
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS.
Lauda F; Fangerau T; Javaheripour-Otto K; Pinkhardt E; Kassubek J; Tumani H
J Neurol; 2015; 262(4):1055-7. PubMed ID: 25663412
[No Abstract] [Full Text] [Related]
19. Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
Pitarokoili K; Hellwig K; Lukas C; Gold R
Mult Scler; 2017 Mar; 23(3):483-486. PubMed ID: 28260421
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
